Takeda Adds To Oncology Holdings By Purchasing Intellikine And Two PI3K Clinical Candidates
This article was originally published in PharmAsia News
Takeda’s Millennium oncology unit will absorb Intellikine’s programs in a deal paying $190 million upfront to buy out the privately held biotech.
You may also be interested in...
Infinity In-Licenses Portfolio Of PI3 Kinase Inhibitors For Inflammatory Diseases
Deal is the historically oncology-focused Infinity's first pipeline-building move since it began a strategic alliance with Purdue Pharma and the latter's European affiliate Mundipharma in late 2008.
Intellikine is developing a group of compounds capable of selectively inhibiting different PI3K isoforms. It can mix and match components to achieve a variety of therapeutic goals. The company's lead program, an mTOR inhibitor for cancer, is nearing the clinic. The start-up also sees significant potential for its PI3 kinase inhibitors in inflammatory diseases and hopes to begin a Phase I trial in that area next year.
Falling At The Start Line: Chinese Firms Face Multiple Commercial Challenges Beyond Price, Coverage
Sales of a global first-in-class dermatology drug that gained its first approval in China are falling well behind those of its overseas counterpart. In this case study, Scrip takes a deep dive into the multiple underlying factors determining success in the world's second-largest pharma market beyond pricing and reimbursement coverage, including complex hospital entry, dual channels and competition considerations.